1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

12 Nov 2024
Admin
News Article

Alteogen Enters into Agreement with Daiichi Sankyo for ENHERTU® Development Using Hybrozyme™ Technology

Overview

Alteogen has announced an exclusive licensing agreement with Daiichi Sankyo granting the latter global rights to leverage ALT-B4, Alteogen’s innovative hyaluronidase created with Hybrozyme™ Technology.

About ALT-B4

ALT-B4 is Alteogen’s proprietary human recombinant hyaluronidase enzyme, developed with the company’s Hybrozyme™ Technology, allowing drugs typically delivered through intravenous (IV) infusion to be administered subcutaneously.

Benefits of Technology

This technology will be used to develop and commercialize a subcutaneous version of ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2-targeting antibody drug conjugate (ADC) jointly developed by Daiichi Sankyo and AstraZeneca.

Terms of the Agreement

Under the terms of the agreement, Alteogen will receive an initial payment and may earn additional milestone payments, contingent on the progress of specified development, regulatory, and sales targets met by Daiichi Sankyo.

Tiered Royalties: for Alteogen

Alteogen is also set to receive tiered royalties based on product sales following commercialization.
Additionally, Alteogen will supply ALT-B4 to Daiichi Sankyo for both clinical and commercial needs.

This is achieved by temporarily hydrolysing hyaluronan in the extracellular matrix, thus enabling the subcutaneous administration of large-volume medications.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!